Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood test may forecast recovery in elderly infection patients

NCT ID NCT07770334

Knowledge-focused Sponsor: Barzilai Medical Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 18, 2026 · Last updated Aug 19, 2026 · Updated 1 time

Summary

This study looks at whether a blood test called procalcitonin can help predict how older adults hospitalized with infections will fare. Researchers will review medical records from 1,000 patients to see if procalcitonin levels at admission are linked to outcomes like death, length of hospital stay, and need for intensive care. The goal is to see if this marker, already used in younger patients, is also useful for older patients in general medical wards.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If procalcitonin proves reliable in older patients, it could help doctors better predict recovery and complications, improving care for this vulnerable group.
What could go wrong
This is an observational study, so it cannot prove cause and effect. Results may not apply to all patients, and procalcitonin levels can be influenced by other conditions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 1,000 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

All patients hospitalized in internal medicine and geriatric wards with a diagnosis of acute infectious disease who underwent procalcitonin testing, starting in 2020.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * All patients hospitalized in internal medicine and geriatric wards with a diagnosis of acute infectious disease who underwent procalcitonin testing, starting in 2020. Exclusion Criteria: * Age under 18 * Causes for false positive elevated cacitonin: * Extensive burns * Major operation in the last 30 days * Major trauma in the last 30 days. * Severe pancreatitis * Cardiogenic shock * Small Cell Lung Cancer * Thyroid gland malignancy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Infection are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Infections infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Infection Internal medicine patients Procalcitonin

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.